<DOC>
	<DOCNO>NCT01782963</DOCNO>
	<brief_summary>This research study Phase II clinical trial . Phase II clinical trial test effectiveness investigational combination drug . The purpose learn whether combination drug work treat specific cancer . `` Investigational '' mean combination drug still study . It also mean research doctor try find . Examples want learn safest dose use , side effect may cause , combination drug work treat different type cancer .</brief_summary>
	<brief_title>Lenalidomide/Bortezomib/Dexamethasone Multiple Myeloma ( MM )</brief_title>
	<detailed_description>If willing participate study ask undergo screening procedure test confirm eligible . Many test procedure likely part regular cancer care . They may do even turn take part research study . If test procedure recently , may may repeat . These test procedure include : medical history , physical exam , performance status , vital sign , neurological exam , bone imaging study , chest x-ray , bone marrow aspirate , ECG , blood test urine test . If test show eligible participate research study , begin study treatment . If meet eligibility criterion , able participate research study . For cycle 1-9 ( cycle last 35 day ) receive follow : Lenalidomide-once day Days 1-21 . You take Lenalidomide mouth time day . Bortezomib- day Days 1 , 8 , 15 22 . If one first ten patient enrol get Bortezomib intravenous injection first cycle . You get Bortezomib injection skin cycle . If one first 10 patient enrol get Bortezomib injection skin cycle . Dexamethasone-if 75 year old young get Dexamethasone Days 1 , 2 , 8 , 9 , 15 , 16 , 22 23 . If 75 year old get Dexamethasone Days 1 , 8 , 15 22 . You take Dexamethasone mouth time day . For cycle 10-15 ( cycle last 28 day ) receive follow : Lenalidomide-once day Days 1-21 . You take Lenalidomide mouth time day . Bortezomib-Once day Days 1 15 . You get Bortezomib injection skin . You give drug diary record take dos drug . The study staff tell complete diary . During study come clinic visit . The test procedures do visit list : Day 1 cycle : question health , medication etc. , physical exam , performance status , vital sign , neurological exam , questionnaire , bone imaging study , bone marrow aspirate , blood test , pregnancy test , education counseling , collection bone marrow , plasma serum ( cycle 1 ) , urine test . Day 8 cycle 1-9 : question health , medication etc. , vital sign , blood test . Day 15 cycle : question health , medication , etc. , vital sign , blood test , pregnancy test . Day 22 cycle 1-9 : question health , medication , etc. , vital sign , blood test . After final dose study drug End Treatment visit . The following test procedure do visit : question health , medication etc. , physical exam , performance status , vital sign , neurological exam , questionnaire , bone imaging study , bone marrow aspirate , blood test , pregnancy test , education counseling , collection bone marrow , plasma serum , urine test . After End Treatment visit , would like follow status every 2 month disease get bad . The following test procedures do follow-up visit : question health , medication , symptom etc. , blood test urine test . If one first twenty patient enrol study also ask provide additional blood sample study body study drug . We take one sample five time point cycle 1 2 . Collection sample may require come back clinic additional day receive study drug . You research study 15 month . You study maximum 15 cycle . If disease get bad 15th cycle take study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Documented symptomatic myeloma , organ damage relate myeloma Myeloma measurable either serum urine evaluation monoclonal component assay serum free light chain Must commit complete abstinence heterosexual contact begin two acceptable method birth control , one highly effective method one additional effective ( barrier ) method Eligible autologous stem cell transplantation HIV positive combination antiretroviral therapy Pregnant breastfeeding Treated prior systemic therapy Primary amyloidosis myeloma complicate amyloidosis Receiving investigational agent within 14 day start trial trial Known brain metastasis Poor tolerability know allergy study drug similar compound Intercurrent illness Previous history another malignant condition except basal cell carcinoma stage I cervical cancer Inability comply antithrombotic treatment regimen Peripheral neuropathy great equal grade 2</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Newly diagnose</keyword>
</DOC>